Synonyms: example 9 [US10053477B2] | Qixinke® | WX-0593 | WX0593
iruplinalkib is an approved drug (China (2023))
Compound class:
Synthetic organic
Comment: The chemical structure for iruplinalkib (WX-0593) was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a tyrosine kinase inhibitor and antineoplastic agent. It is one of the compounds claimed in Qilu Pharmaceutical's ALK inhibitor patent US10053477B2 [1]. Subsequent information described iruplinalkib as an orally bioactive selective ALK/ROS1 tyrosine kinase inhibitor [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Ding Z, Zhang M, Chen S, Liu X, Zhu Y, Fan Y, Zhao B, Zhang L, Yang Y, Zheng Q et al.. (2018)
Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide. Patent number: US10053477B2. Assignee: Qilu Pharmaceutical Co Ltd. Priority date: 04/07/2014. Publication date: 21/08/2018. |
2. Keam SJ. (2023)
Iruplinalkib: First Approval. Drugs, 83 (18): 1717-1721. [PMID:38008856] |
3. Shi Y, Chen J, Yang R, Wu H, Wang Z, Yang W, Cui J, Zhang Y, Liu C, Cheng Y et al.. (2024)
Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE). J Thorac Oncol, 19 (6): 912-927. [PMID:38280448] |
4. Shi Y, Fang J, Hao X, Zhang S, Liu Y, Wang L, Chen J, Hu Y, Hang X, Li J et al.. (2022)
Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther, 7 (1): 25. [PMID:35087031] |